Equities

GE Healthcare Technologies Inc

GE Healthcare Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)88.53
  • Today's Change1.74 / 2.00%
  • Shares traded3.51m
  • 1 Year change+33.57%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 18-Sep-24
Select bar for recommendation details.
Recommendations18-Sep-24
Buy4
Outperform8
Hold7
Sell0
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for GE HealthCare Technologies Inc have a median target of 95.00, with a high estimate of 105.00 and a low estimate of 84.00. The median estimate represents a 9.46% increase from the last price of 86.79.
High21.0%105.00
Med9.5%95.00
Low-3.2%84.00

Dividends in USD

Historical dividend information is not available for GE Healthcare Technologies Inc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Jul 31, 2024, GE HealthCare Technologies Inc reported 2nd quarter 2024 earnings of 1.00 per share. This result was in line with the consensus of the 12 analysts following the company and exceeded last year's 2nd quarter results by 8.70%.
The next earnings announcement is expected on Nov 01, 2024.
Average growth rate+3.55%
GE HealthCare Technologies Inc reported annual 2023 earnings of 3.93 per share on Feb 06, 2024.
Average growth rate-15.12%
More ▼

Revenue history & estimates in USD

GE HealthCare Technologies Inc had 2nd quarter 2024 revenues of 4.84bn. This missed the 4.87bn consensus estimate of the 10 analysts following the company. This was 2.80% above the prior year's 2nd quarter results.
Average growth rate+0.36%
GE HealthCare Technologies Inc had revenues for the full year 2023 of 19.55bn. This was 6.60% above the prior year's results.
Average growth rate+6.60%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.